HFSA Heart Failure Seminar: Focus on Guideline-Directed Medical Therapy (GDMT)
Everything you want to know, and not afraid to ask: The evidence, the how, and the challenges.

Original Seminar Date:  April 22,2022
Product Expiration Date: May 6, 2023

The optimization of GDMT in the treatment of HF has been shown to reduce morbidity and mortality and improve patient outcomes. However, many HF patients do not receive GDMT and/or achieve the recommended target dose of their medications. Studies have shown that while most patients are managed by cardiologists or primary care practitioners, GDMT and target doses of medication can also be successfully achieved by expanding this role to other providers. Education on GDMT, optimizing medications, and these successful strategies are needed to expand patient outcomes. This program will provide practitioners with updated information on the universal definition of heart failure, guideline-directed medical therapies (GDMT), and strategies that optimize medical therapies (OMT) to improve patient outcomes.

This program is intended for physicians, nurses, nurse practitioners, physician assistants, and advanced practice professionals that provide care to patients with heart failure.

At the conclusion of this activity, learners will be better able to:

• Identify evidence-based therapies that improve outcomes in HF management
• Recognize and discuss clinical and socio-economic barriers to implementing GDMT to achieve therapeutic success and improve patient outcomes
• Develop strategies to successfully manage the clinical barriers (comorbidities) of implementing GDMT

Freny Vaghaiwalla Mody, MD
Professor of Medicine
David Geffen School of Medicine at UCLA
Director, Heart Failure Program & Preventive Cardiology Program
Veterans Administration of Greater Los Angeles Health Care System, Los Angeles, CA
Disclosure(s): Nothing to Disclose

Janet Crawford, APRN, DNP, MBA, MSN, ACNP-BC, FNP
Orlando Health Heart and Vascular Institute, Orlando, FL
Disclosure(s): Nothing to Disclose

Courtney Shakowski, PharmD, FHFSA
Clinical Assistant Professor
University of Colorado School of Pharmacy
Clinical Pharmacy Specialist – Critical Care / Cardiology
University of Colorado Hospital,  Aurora, CO
Disclosure(s): Nothing to Disclose

Larry A. Allen, MD, MHS
Professor of Medicine, Kenneth Poirier Endowed Chair
Associate Head for Clinical Affairs, Cardiology
Medical Director, Advanced Heart Failure
University of Colorado, School of Medicine, Aurora, CO
Disclosure(s): Consultant: ACI Clinical, Boston Scientific, Novartis, and Cytokinetics, Inc.

Robert L Page II, PharmD, MSPH, FHFSA
Professor of Clinical Pharmacy
University of Colorado Skaggs School of Pharmacy
Clinical Specialist, Division of Cardiology
University of Colorado Health System, Aurora, CO
Disclosure(s): Nothing to Disclose

Lynne Warner Stevenson, MD, FHFSA
Lisa M. Jacobson Professor of Cardiovascular Medicine and Director of Cardiomyopathy
Vanderbilt University School of Medicine, Nashville, TN
Disclosure(s): Nothing to Disclose

Welcome and Introduction
Freny Vaghaiwalla Mody, MD
Janet Crawford, APRN, DNP, MBA, MSN, ACNP-BC, FNP
Courtney Shakowski, PharmD, FHFSA

Guideline-Directed Medical Therapy (GDMT): Evidence and Benefits and Live Q&A
Larry A. Allen, MD, MHS

Tearing Down the Barriers to Optimizing GDMT: Considerations in the Patient with Heart Failure and Live Q&A
Robert L Page II, PharmD, MSPH, FHFSA

Personalizing Therapy for the Tough Cases and Strategies for Navigating Comorbidities Which Become Barriers to Success and Live Q&A
Lynne Warner Stevenson, MD, FHFSA

Panel Discussion
Faculty

In support of improving patient care, the Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Heart Failure Society of America designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Learners should claim only the credit commensurate with the extent of their participation in the activity.

This educational activity is approved for nursing continuing professional development (NCPD) units by the Heart Failure Society of America, an accredited provider of the American Nurses Credentialing Center. This activity is approved for a maximum 1.50 contact hours. Learners should claim only the credit commensurate with the extent of their participation in the activity.  

The Heart Failure Society of America is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (CPE). This event is accredited for up to 1.50 contact hours of knowledge-based CPE.

ACPE Universal Activity Number (UAN): JA4008267-0000-22-001-L04-P

The Heart Failure Society of America acknowledges Merck for providing an unrestricted educational grant to support the Heart Failure Seminar: Focus on Guideline-Directed Medical Therapy (GDMT).